With the introduction of several novel medications, including angiotensin receptor neprilysin inhibitors and sodium-glucose cotransporter 2 inhibitors, in addition to conventional beta-blockers and mineralocorticoid receptor antagonists, mortality and morbidity in patients with heart failure improved significantly [...]